StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Regeneron Pharma (REGN) PT Raised to $480 at Oppenheimer
February 7, 2019 8:15 AM
Oppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $480.00 (from $440.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Regeneron (REGN) Announces 1-Yr. Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
February 11, 2019 5:44 AM
Regeneron Pharma (REGN) PT Raised to $412 at BMO Capital
February 7, 2019 7:48 AM
Regeneron (REGN) Tops Expectations Across Product Line, PT To $410 At Baird
February 7, 2019 6:29 AM
Regeneron Pharma (REGN) PT Raised to $325 at Barclays
February 7, 2019 4:59 AM
Form SC 13G/A REGENERON PHARMACEUTICAL Filed by: BlackRock Inc.
February 6, 2019 5:33 PM
Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital
February 6, 2019 3:25 PM
Form 8-K REGENERON PHARMACEUTICAL For: Feb 06
February 6, 2019 7:49 AM
Regeneron (REGN) Tops Q4 EPS by $1.06, Revenues Beat; Offers FY19 Financial Guidance
February 6, 2019 6:32 AM
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
February 6, 2019 6:30 AM
